Setup, so nobody has to ask: a residual-solvent screen · a GLP-1 receptor agonist.
I suspect the honest answer is that it depends, in which case I would like to know on what.
Assume I can obtain either option without difficulty, so availability is not the deciding factor.
Is there a defensible reason to prefer one, or is this a coin flip?